108 related articles for article (PubMed ID: 26549419)
1. Expanded metabolomics approach to profiling endogenous carbohydrates in the serum of ovarian cancer patients.
Cheng Y; Li L; Zhu B; Liu F; Wang Y; Gu X; Yan C
J Sep Sci; 2016 Jan; 39(2):316-23. PubMed ID: 26549419
[TBL] [Abstract][Full Text] [Related]
2. Fast quantification of endogenous carbohydrates in plasma using hydrophilic interaction liquid chromatography coupled with tandem mass spectrometry.
Zhu B; Liu F; Li X; Wang Y; Gu X; Dai J; Wang G; Cheng Y; Yan C
J Sep Sci; 2015 Jan; 38(1):34-41. PubMed ID: 25359182
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer detection using targeted plasma metabolomics.
Jasbi P; Wang D; Cheng SL; Fei Q; Cui JY; Liu L; Wei Y; Raftery D; Gu H
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Jan; 1105():26-37. PubMed ID: 30562627
[TBL] [Abstract][Full Text] [Related]
4. Predicting ovarian cancer recurrence by plasma metabolic profiles before and after surgery.
Zhang F; Zhang Y; Ke C; Li A; Wang W; Yang K; Liu H; Xie H; Deng K; Zhao W; Yang C; Lou G; Hou Y; Li K
Metabolomics; 2018 Apr; 14(5):65. PubMed ID: 30830339
[TBL] [Abstract][Full Text] [Related]
5. Urinary hydrophilic and hydrophobic metabolic profiling based on liquid chromatography-mass spectrometry methods: Differential metabolite discovery specific to ovarian cancer.
Chen J; Zhou L; Zhang X; Lu X; Cao R; Xu C; Xu G
Electrophoresis; 2012 Nov; 33(22):3361-9. PubMed ID: 23109122
[TBL] [Abstract][Full Text] [Related]
6. Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors.
Buas MF; Gu H; Djukovic D; Zhu J; Drescher CW; Urban N; Raftery D; Li CI
Gynecol Oncol; 2016 Jan; 140(1):138-44. PubMed ID: 26521694
[TBL] [Abstract][Full Text] [Related]
7. Metabolomic serum profiling detects early-stage high-grade serous ovarian cancer in a mouse model.
Jones CM; Monge ME; Kim J; Matzuk MM; Fernández FM
J Proteome Res; 2015 Feb; 14(2):917-27. PubMed ID: 25567202
[TBL] [Abstract][Full Text] [Related]
8. Identification of metabolic biomarkers to diagnose epithelial ovarian cancer using a UPLC/QTOF/MS platform.
Fan L; Zhang W; Yin M; Zhang T; Wu X; Zhang H; Sun M; Li Z; Hou Y; Zhou X; Lou G; Li K
Acta Oncol; 2012 Apr; 51(4):473-9. PubMed ID: 22283470
[TBL] [Abstract][Full Text] [Related]
9. Identification of Potential Biomarkers and Metabolic Profiling of Serum in Ovarian Cancer Patients Using UPLC/Q-TOF MS.
Yang W; Mu T; Jiang J; Sun Q; Hou X; Sun Y; Zhong L; Wang C; Sun C
Cell Physiol Biochem; 2018; 51(3):1134-1148. PubMed ID: 30476914
[TBL] [Abstract][Full Text] [Related]
10. Metabolomic biomarkers for benign conditions and malignant ovarian cancer: Advancing early diagnosis.
Zhang W; Lai Z; Liang X; Yuan Z; Yuan Y; Wang Z; Peng P; Xia L; Yang X; Li Z
Clin Chim Acta; 2024 Jun; 560():119734. PubMed ID: 38777245
[TBL] [Abstract][Full Text] [Related]
11. Untargeted mass spectrometry-based metabolomic profiling of pleural effusions: fatty acids as novel cancer biomarkers for malignant pleural effusions.
Lam CW; Law CY
J Proteome Res; 2014 Sep; 13(9):4040-6. PubMed ID: 25117182
[TBL] [Abstract][Full Text] [Related]
12. Identification and confirmation of differentially expressed fucosylated glycoproteins in the serum of ovarian cancer patients using a lectin array and LC-MS/MS.
Wu J; Xie X; Liu Y; He J; Benitez R; Buckanovich RJ; Lubman DM
J Proteome Res; 2012 Sep; 11(9):4541-52. PubMed ID: 22827608
[TBL] [Abstract][Full Text] [Related]
13. Wide spectrum targeted metabolomics identifies potential ovarian cancer biomarkers.
Plewa S; Horała A; Dereziński P; Nowak-Markwitz E; Matysiak J; Kokot ZJ
Life Sci; 2019 Apr; 222():235-244. PubMed ID: 30853626
[TBL] [Abstract][Full Text] [Related]
14. LC-MS-based metabolomics in the clinical laboratory.
Becker S; Kortz L; Helmschrodt C; Thiery J; Ceglarek U
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Feb; 883-884():68-75. PubMed ID: 22074957
[TBL] [Abstract][Full Text] [Related]
15. Colorectal Cancer Detection Using Targeted LC-MS Metabolic Profiling.
Djukovic D; Zhang J; Raftery D
Methods Mol Biol; 2018; 1765():229-240. PubMed ID: 29589312
[TBL] [Abstract][Full Text] [Related]
16. An integrated metabolomics workflow for the quantification of sulfur pathway intermediates employing thiol protection with N-ethyl maleimide and hydrophilic interaction liquid chromatography tandem mass spectrometry.
Ortmayr K; Schwaiger M; Hann S; Koellensperger G
Analyst; 2015 Nov; 140(22):7687-95. PubMed ID: 26451393
[TBL] [Abstract][Full Text] [Related]
17. Development of a nanoLC LTQ orbitrap mass spectrometric method for profiling glycans derived from plasma from healthy, benign tumor control, and epithelial ovarian cancer patients.
Bereman MS; Williams TI; Muddiman DC
Anal Chem; 2009 Feb; 81(3):1130-6. PubMed ID: 19113831
[TBL] [Abstract][Full Text] [Related]
18. Quantitative profiling of polar primary metabolites using hydrophilic interaction ultrahigh performance liquid chromatography-tandem mass spectrometry.
Gika HG; Theodoridis GA; Vrhovsek U; Mattivi F
J Chromatogr A; 2012 Oct; 1259():121-7. PubMed ID: 22381888
[TBL] [Abstract][Full Text] [Related]
19. Integrated ionization approach for RRLC-MS/MS-based metabonomics: finding potential biomarkers for lung cancer.
An Z; Chen Y; Zhang R; Song Y; Sun J; He J; Bai J; Dong L; Zhan Q; Abliz Z
J Proteome Res; 2010 Aug; 9(8):4071-81. PubMed ID: 20560663
[TBL] [Abstract][Full Text] [Related]
20. Development of a universal metabolome-standard method for long-term LC-MS metabolome profiling and its application for bladder cancer urine-metabolite-biomarker discovery.
Peng J; Chen YT; Chen CL; Li L
Anal Chem; 2014 Jul; 86(13):6540-7. PubMed ID: 24877652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
